Looks like an exciting 2013 from the J.P. Morgan Healthcare Conference

>
4 of 40
<

John McDonough, President and CEO of T2 Biosystems

John McDonough, T2 Biosystems' president and CEO, came to this year's J.P. Morgan event to meet potential investors plus diagnostics companies that might want to selectively partner on new uses for T2's signature product--magnetic resonance imaging tech that can help speed up a diagnostic process by eliminating the need for cleaning up a sample for culturing. The 2012 Fierce 15 company will soon launch a clinical trial of a rapid diagnostic assay for Candida infections. But McDonough explained that T2's tech could also be used for various cancer diagnostics, or even to measure clotting time. McDonough, a 10-year veteran of the annual JPM conference, said attendees are showing "more optimism than I have seen in the last couple of years."